Literature DB >> 17488668

Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.

Stefan Kuhle1, Pablo Eulmesekian, Brian Kavanagh, Patricia Massicotte, Patsy Vegh, Alice Lau, Lesley G Mitchell.   

Abstract

UNLABELLED: The activated partial thromboplastin time (aPTT) and anti-Xa activity are used for monitoring unfractionated heparin (UFH) therapy in children and may not be optimal.
OBJECTIVE: Determine correlations of aPTT, anti-Xa and UFH dose in children. Single centre prospective cohort study in children receiving UFH. The aPTT and anti-Xa results from routine coagulation monitoring were collected. Thirty-nine children (median age 18 days) were enrolled. There was no relationship between aPTT and UFH dose (r2=0.12) or anti-Xa and UFH dose (r2=0.03) or aPTT and anti-Xa (r2=0.22). aPTT and anti-Xa do not accurately monitor UFH therapy in children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488668     DOI: 10.3324/haematol.10696

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Revisiting the Pharmacology of Unfractionated Heparin.

Authors:  Abdallah Derbalah; Stephen Duffull; Fiona Newall; Katie Moynihan; Hesham Al-Sallami
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

Review 3.  Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.

Authors:  Donald L Yee; Sarah H O'Brien; Guy Young
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

Review 4.  Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients.

Authors:  Hwa Jin Cho; Do Wan Kim; Gwan Sic Kim; In Seok Jeong
Journal:  Chonnam Med J       Date:  2017-05-25

Review 5.  Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.

Authors:  Werner Streif; Walter Ageno
Journal:  Wien Med Wochenschr       Date:  2011-02

6.  A Nanoscale Tool for Photoacoustic-Based Measurements of Clotting Time and Therapeutic Drug Monitoring of Heparin.

Authors:  Junxin Wang; Fang Chen; Santiago J Arconada-Alvarez; James Hartanto; Li-Peng Yap; Ryan Park; Fang Wang; Ivetta Vorobyova; Grant Dagliyan; Peter S Conti; Jesse V Jokerst
Journal:  Nano Lett       Date:  2016-09-28       Impact factor: 11.189

7.  Monitoring unfractionated heparin in pediatric patients with congenital heart disease having cardiac catheterization or cardiac surgery.

Authors:  G G Kim; S El Rouby; J Thompson; A Gupta; J Williams; D R Jobes
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

8.  Utility and correlation of known anticoagulation parameters in the management of pediatric ventricular assist devices.

Authors:  Ajay K Bhatia; Mouhammad Yabrodi; Mallory Carroll; Silvia Bunting; Kirk Kanter; Kevin O Maher; Shriprasad R Deshpande
Journal:  World J Cardiol       Date:  2017-09-26

9.  Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials.

Authors:  Hugo Maas; Savion Gropper; Fenglei Huang; Joachim Stangier; Igor Tartakovsky; Martina Brueckmann; Jacqueline M L Halton; Lesley G Mitchell
Journal:  Thromb Haemost       Date:  2018-08-15       Impact factor: 5.249

Review 10.  Anticoagulation Management and Monitoring during Pediatric Extracorporeal Life Support: A Review of Current Issues.

Authors:  Lindsay M Ryerson; Laurence L Lequier
Journal:  Front Pediatr       Date:  2016-06-22       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.